228 related articles for article (PubMed ID: 24254560)
1. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
3. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
5. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
Ueno T; Uehara S; Nakahata K; Okuyama H
Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
[TBL] [Abstract][Full Text] [Related]
6. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
7. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
[TBL] [Abstract][Full Text] [Related]
8. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
[TBL] [Abstract][Full Text] [Related]
9. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
11. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
[TBL] [Abstract][Full Text] [Related]
12. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
[TBL] [Abstract][Full Text] [Related]
13. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M
Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508
[TBL] [Abstract][Full Text] [Related]
15. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
[TBL] [Abstract][Full Text] [Related]
16. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
[TBL] [Abstract][Full Text] [Related]
17. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
[TBL] [Abstract][Full Text] [Related]
18. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
[TBL] [Abstract][Full Text] [Related]
19. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Mol Cancer Ther; 2015 Jun; 14(6):1404-13. PubMed ID: 25808836
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
